Who are carbidopa-levodopa (Sinemet)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sinemet plus, CLE, Oral IR-LD/CD, IPX066, IR CD-LD.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carbidopa-levodopa-sinemet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

carbidopa-levodopa (Sinemet) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

carbidopa-levodopa (Sinemet) (carbidopa-levodopa (Sinemet)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine replacement therapy. Area: Neurology.

marketed Dopamine replacement therapy Aromatic amino acid decarboxylase (AADC); dopamine pathway Neurology Small molecule Live · refreshed every 30 min

Target snapshot

carbidopa-levodopa (Sinemet) (carbidopa-levodopa (Sinemet)) — Baylor College of Medicine. Carbidopa inhibits peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain where it is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
carbidopa-levodopa (Sinemet) TARGET	carbidopa-levodopa (Sinemet)	Baylor College of Medicine	marketed	Dopamine replacement therapy	Aromatic amino acid decarboxylase (AADC); dopamine pathway
sinemet plus	sinemet plus	Hospital de Granollers	marketed	Dopamine replacement therapy with COMT inhibitor	Dopamine pathway; COMT enzyme
CLE	CLE	Impax Laboratories, LLC	marketed	Dopamine replacement therapy / Levodopa combination	Dopamine pathway; decarboxylase inhibition
Oral IR-LD/CD	Oral IR-LD/CD	NeuroDerm Ltd.	phase 3	Dopamine replacement therapy	Dopamine pathway; aromatic amino acid decarboxylase inhibition
IPX066	IPX066	Impax Laboratories, LLC	phase 3	Dopamine replacement therapy; extended-release levodopa/carbidopa combination	Dopamine pathway (via levodopa conversion to dopamine)
IR CD-LD	IR CD-LD	Impax Laboratories, LLC	phase 3	Dopamine replacement therapy / Decarboxylase inhibitor combination	Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine replacement therapy class)

Baylor College of Medicine · 1 drug in this class
NeuroDerm Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). carbidopa-levodopa (Sinemet) — Competitive Intelligence Brief. https://druglandscape.com/ci/carbidopa-levodopa-sinemet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab